Is Botox Effective in Relieving Pain From Knee Osteoarthritis?

• ClinicalTrials.gov Identifier: NCT00279903
• Recruitment Status: Completed
• First Posted: January 20, 2006
• Last Update Posted: November 7, 2012
• Sponsor: Mayo Clinic
• Information provided by: Mayo Clinic

Study Description

Brief Summary:

Patients with painful knee osteoarthritis will be randomly allocated to one of three groups. Each group will receive a knee injection of: 1) cortisone, 2) low dose Botox, or 3) high dose Botox. Patients will then be followed for 6 months to see if they have significant pain relief or improvement in their activity level after the injection.

Condition or disease	Intervention/treatment	Phase
Osteoarthritis, Knee	Drug: Botulinum toxin type A (Btx-A); Drug: Cortisone	Phase 1

Detailed Description:

Abstract Botulinum toxin type A (Btx-A) has been extensively studied and used clinically for its muscle paralyzing effects, but there is a growing body of evidence to support a role in pain modulation. Symptomatic osteoarthritis is a leading cause of pain, functional impairment, and disability, with significant indirect costs to society. Preliminary evidence suggests that Btx-A has a significant nociceptive effect, when injected intra-articularly, in to painful joints. The proposed study will evaluate the efficacy and safety of Btx-A injected intra-articularly in 60 subjects with moderate pain and functional impairment secondary to knee osteoarthritis, in a randomized, cortisone-controlled, double blind study, over a 6 month follow up period. If Btx-A is shown to be of equal or greater efficacy than cortisone in this patient population, it may be an excellent second line treatment for osteoarthritis, in multiple joints, where surgery is contraindicated or deferred due to age, comorbidities, or patient preference. Further studies examining the mechanism of action at the biochemical level, the clinical effect of Btx-A in other joints (in both osteoarthritis and inflammatory arthritis), the efficacy of Btx-A compared to hyaluronic acid (the only currently available injectable alternative to cortisone), and the side effect profile (effect on adjacent muscle strength, joint position sense, and long-term outcomes) would be indicated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 62 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.
• Study Start Date: November 2005
• Actual Primary Completion Date: August 2008
• Actual Study Completion Date: August 2008

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Cortisone	Drug: Cortisone; 1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.; Other Name: Medrol
Experimental: Low Dose Btx-A	Drug: Botulinum toxin type A (Btx-A); Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.; Other Name: Botox
Experimental: High Dose Btx-A	Drug: Botulinum toxin type A (Btx-A); Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.; Other Name: Botox

Outcome Measures

Primary Outcome Measures :

1. Decrease in pain at 8 weeks post injection

Secondary Outcome Measures :

1. Improvement in function at 2, 4, 8, 12, 26 weeks
2. Improvement in quality of life at 2, 4, 8, 12, 26 weeks
3. Decrease in pain at 2, 4, 12, 26 weeks

Eligibility Criteria

• Ages Eligible for Study: 40 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria:

1. A history of knee joint pain for greater than 6 months.
2. Medial or lateral tibiofemoral joint line tenderness.
3. Unilateral knee pain 6/10 or greater, on average, on the visual analog scale (VAS), that interferes with function most days per week.
4. Prior failed treatment with acetaminophen and/or non steroidal anti-inflammatory medications, and physical therapy (quadriceps strengthening).
5. Kellgren grade II or III radiographic changes of osteoarthritis.

Exclusion criteria:

1. Age less than 40 years.
2. Anticoagulation with warfarin or heparin.
3. Known allergy or sensitivity to any of the components of the study medications.
4. Body mass index greater than 35.
5. Previous major reconstructive surgery on the affected knee.
6. Previous arthroscopic surgery on the affected knee in the past 12 months.
7. History of crystal induced arthropathy.
8. Use of aminoglycoside antibiotics, curare-like agents, or history of neuromuscular disease such as myasthenia gravis, amyotrophic lateral sclerosis, or myopathy.
9. History of or evidence of active rheumatologic disease, diabetes, severe peripheral neuropathy, clinically evident cardiac or respiratory disease that interferes with functional status, or other serious diseases, including psychiatric disorders.
10. Evidence of recent alcohol or drug abuse, or history of medication misuse or addiction.
11. Females who are pregnant, breastfeeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
12. Intra-articular (knee) or systemic steroids in the past 6 months, or intra-articular knee hyaluronic acid injection in the past 6 months.
13. Patients who rate their average daily pain as less than 6 on a 10 point VAS scale at the screening visit.
14. Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.

Contacts and Locations

Locations

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Mayo Clinic

Investigators

• Principal Investigator: Andrea J. Boon, M.D.; Mayo Clinic

More Information

• ClinicalTrials.gov Identifier: NCT00279903
• Other Study ID Numbers: 1565-05
• First Posted: January 20, 2006
• Last Update Posted: November 7, 2012
• Last Verified: November 2012

Additional relevant MeSH terms:

Osteoarthritis; Osteoarthritis, Knee; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Cortisone; Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA; Acetylcholine Release Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Neurotransmitter Agents; Physiological Effects of Drugs; Neuromuscular Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents